IP Library Granted Patent US 8,709,449
Granted Patent B2
US 8,709,449 · App. 11/055,923 · Granted Apr 29, 2014

Methods and compositions for improving photodynamic therapy through administration of lipids

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,709,449
App. No.
11/055,923
Granted
Apr 29, 2014
Kind
B2
Abstract

The present invention provides methods and compositions for increasing the effectiveness of photodynamic therapy (“PDT”) and for reducing the duration of skin phototoxicity associated with PDT treatment. The disclosed methods generally include the administration of a lipid composition before, during, or after the administration of photosensitizers used in the PDT treatment protocol. The lipids are preferably phospholipids. It was discovered that the disclosed methods resulted in a more rapid clearance of photosensitizers from the skin and other tissue of patients, which results in a shorter period of skin phototoxicity after PDT treatment. The present invention also provides a composition which is preferably comprised of non-polar photosensitizers and phospholipids.

Claims (10)

1. A method of photodynamic therapy comprising the steps of:

a) administering a lipophilic photosensitizer to a treatment area in a patient;

b) at a suitable time after step a), irradiating said treatment area with radiation having at least a wavelength suitable to activate said photosensitizer to destroy target tissue in said treatment area; and

c) following irradiation of the treatment area, administering a formulation comprising a lipid emulsion to the patient.

2. The method of claim 1 , wherein the formulation comprising said lipid emulsion is administered at least 5 hours following irradiation of the treatment area.

3. The method of claim 2 , wherein the formulation comprising said lipid emulsion is administered between 5 and 10 hours following irradiation of the treatment area.

4. The method of claim 3 , wherein the formulation comprising said lipid emulsion is Lipofundin.

5. The method of claim 1 , wherein said lipid emulsion comprises soybean oil, medium-chain triglycerides, and phospholipids from eggs.

6. The method according to claim 1 , wherein said lipid emulsion includes phospholipids as a component of the formulation.

7. The method according to claim 1 , wherein said lipophilic photosensitizer is selected from the group consisting of porphyrins, phthalocyanines, metallo derivative thereof, dyes, and synthetic photosensitizers.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 23, 2016
From: BIOLITEC PHARMA MARKETING LTD.
To: BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG
Reel/Frame 041182/0578 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 2, 2009
From: BIOLITEC, INC.
To: BIOLITEC PHARMA MARKETING LTD.
Reel/Frame 022482/0944 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 2, 2009
From: CERAMOPTEC INDUSTRIES, INC.
To: BIOLITEC, INC.
Reel/Frame 022482/0956 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 10, 2005
From: ALBRECHT, VOLKER; GRAFE, SUSANNA
To: CERAMOPTEC INDUSTRIES, INC.
Reel/Frame 016293/0649 →